Skip Navigation


JAC Advance Access originally published online on November 4, 2008
Journal of Antimicrobial Chemotherapy 2009 63(1):7-10; doi:10.1093/jac/dkn455
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
63/1/7    most recent
dkn455v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Marsden, M. D.
Right arrow Articles by Zack, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marsden, M. D.
Right arrow Articles by Zack, J. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Leading articles

Eradication of HIV: current challenges and new directions

Matthew D. Marsden1,2 and Jerome A. Zack1,2,3,*

1 Department of Medicine, Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA 2 UCLA AIDS Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA 3 Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA

* Corresponding author. David Geffen School of Medicine at UCLA, 615 Charles E Young Drive South, BSRB 173, Los Angeles, CA 90095-7363, USA. Tel: +1-310-825-0876; Fax: +1-310-267-1875; E-mail: jzack{at}ucla.edu

Highly active antiretroviral therapy (HAART) can potently suppress human immunodeficiency virus (HIV) replication and prevent progression to AIDS. However, HAART does not cure infected patients. Instead, HIV persists in latently infected CD4+ T cells and various cryptic cellular reservoirs. Hence, under current therapy regimens, patients must continue taking HAART for the remainder of their lives. Eliminating residual replication-competent virus is critical if eradication of HIV is to be achieved. While this challenge is formidable, we describe here a number of innovative approaches intended to further deplete HIV in HAART-treated patients. New antiretroviral drugs that target different viral proteins and stages of the virus life cycle, compounds that enhance anti-HIV immune responses and novel gene therapy approaches may each play a role in improving long-term suppression of the virus. Moreover, methods for more specifically and efficiently inducing HIV from latency and eliminating the newly activated host cells are also under development.

Keywords: latency , HAART , antiretroviral , therapy , AIDS


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Virol.Home page
M. J. Dapp, C. L. Clouser, S. Patterson, and L. M. Mansky
5-Azacytidine Can Induce Lethal Mutagenesis in Human Immunodeficiency Virus Type 1
J. Virol., November 15, 2009; 83(22): 11950 - 11958.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.